Iovance Biotherapeutics Inc at TD Cowen Healthcare Conference Transcript
All right. Great. Good morning, everyone. Tyler Van Buren here, Senior Biotech Analyst at TD Cowen. Thank you very much for joining TD Cowen's 46 Annual Healthcare Conference. For our next session, we have a hybrid presentation followed by Q&A, with Iovance. It's, my pleasure to introduce Corleen Roche, the Chief Financial Officer, and Igor Bilinsky, the Chief Operating Officer of Iovance.
Corleen , and Igor, it's a privilege to have you here.
Thank you very much for joining me. I'll go ahead and hand it over to you to kick off the presentation.
Thanks, Tyler. As well as the whole team at Cowan for inviting us to present today. Can you hear me? Sorry, I'm not as loud as Tyler.
I joined Iovance a little more than six months ago. Why? Because I'm so excited about the opportunity for T cell therapy to meaningfully benefit patients across solid tumor cancers, which, by the way, represent more than 90% of all cancers
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
